A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer

Ghoncheh, 2016, Incidence and mortality and epidemiology of breast cancer in the world, Asian Pac. J. Cancer Prev., 17, 43, 10.7314/APJCP.2016.17.S3.43 Ibrahim, 2014, Cancer incidence in egypt: results of the national population-based cancer registry program, J. Cancer Epidemiol., 2014, 437971, 10.1155/2014/437971 Burridge, 2016, Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity, Nat. Med., 22, 547, 10.1038/nm.4087 Cianfrocca, 2004, Prognostic and predictive factors in early-stage breast cancer, Oncologist, 9, 606, 10.1634/theoncologist.9-6-606 Rivera, 2002, Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease 831, Breast J., 8, 2, 10.1046/j.1524-4741.2002.08002.x Pagani, 2010, International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?, J. Natl. Cancer Inst., 102, 456, 10.1093/jnci/djq029 Wang, 2010, Nanoparticle delivery strategies to target doxorubicin to tumor cells and reduce side effects, Ther. Deliv., 1, 273, 10.4155/tde.10.24 Xing, 2015, Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: a meta-analysis of ten randomized controlled trials, PLoS One, 10, 10.1371/journal.pone.0133569 Poljaková, 2008, The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells, Interdiscip. Toxicol., 1, 186, 10.2478/v10102-010-0036-9 Tewey, 1984, Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II, Science, 226, 466, 10.1126/science.6093249 Tokarska-Schlattner, 2006, New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics, J. Mol. Cell. Cardiol., 41, 389, 10.1016/j.yjmcc.2006.06.009 Pawłowska, 2003, Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase, Oncol. Res., 13, 245, 10.3727/096504003108748294 Swain, 2003, Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials, Cancer, 97, 2869, 10.1002/cncr.11407 Takemura, 2007, Doxorubicin-induced cardiomyopathy. from the cardiotoxic mechanisms to management, Prog. Cardiovasc. Dis., 49, 330, 10.1016/j.pcad.2006.10.002 von Hoff, 1979, Risk factors for doxorubicin-induced congestive heart failure, Ann. Intern. Med., 91, 710, 10.7326/0003-4819-91-5-710 Lipshultz, 1995, Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer, N. Engl. J. Med., 332, 1738, 10.1056/NEJM199506293322602 Wojnowski, 2005, NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity, Circulation, 112, 3754, 10.1161/CIRCULATIONAHA.105.576850 Hortobagyi, 1997, Anthracyclines in the treatment of cancer. An overview, Drugs, 54, 1 Weiss, 1992, The anthracyclines: will we ever find a better doxorubicin?, Semin. Oncol., 19, 670 Ferrari, 2005, Cancer nanotechnology: opportunities and challenges, Nat. Rev. Cancer, 5, 161, 10.1038/nrc1566 Couvreur, 2006, Nanotechnology: intelligent design to treat complex disease, Pharm. Res., 23, 1417, 10.1007/s11095-006-0284-8 Lao, 2013, Liposomal Doxorubicin in the treatment of breast cancer patients: a review, J. Drug Deliv., 12 Anselmo, 2016, Nanoparticles in the clinic, Bioeng. Transl. Med., 1, 10, 10.1002/btm2.10003 Krishna, 1999, The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR), Anticancer Res., 19, 2885 Symon, 1999, Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes, Cancer, 86, 72, 10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1 Deshpande, 2013, Current trends in the use of liposomes for tumor targeting, Nanomedicine, 8, 1509, 10.2217/nnm.13.118 Gao, 2009, Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes, Int. J. Pharm., 374, 145, 10.1016/j.ijpharm.2009.03.018 Ryberg, 2010, Predictive factors for the severity of congestive heart failure after an epirubicin-based treatment for metastatic breast cancer, J. Clin. Oncol. Conference, 10.1200/jco.2010.28.15_suppl.1124 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0 Jones, 2006, Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer, J. Clin. Oncol., 24, 5381, 10.1200/JCO.2006.06.5391 Slamon, 2011, Adjuvant trastuzumab in HER2-positive breast cancer, N. Engl. J. Med., 365, 1273, 10.1056/NEJMoa0910383 O’Brien, 2004, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX???/Doxil??) versus conventional doxorubicin for first-line treatment of metastatic breast cancer, Ann. Oncol., 15, 440, 10.1093/annonc/mdh097 Batist, 2001, Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer, J. Clin. Oncol., 19, 1444, 10.1200/JCO.2001.19.5.1444 Harris, 2002, Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma, Cancer, 94, 25, 10.1002/cncr.10201 Chan, 2004, Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer, Ann. Oncol., 15, 1527, 10.1093/annonc/mdh393 Sparano, 2009, Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracyclin, J. Clin. Oncol., 27, 4522, 10.1200/JCO.2008.20.5013 Al-Batran, 2006, Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer, Oncology, 70, 141, 10.1159/000093005 Al-Batran, 2006, The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial, Br. J. Cancer, 94, 1615, 10.1038/sj.bjc.6603158 Martin, 2004, Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure, Clin. Breast Cancer, 5, 353, 10.3816/CBC.2004.n.041 Ardavanis, 2006, Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study, Cancer Chemother. Pharmacol., 58, 742, 10.1007/s00280-006-0236-3 Chow, 2007, A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer, Am. J. Clin. Oncol., 30, 133, 10.1097/01.coc.0000251400.47711.fe Ulrich-Pur, 2007, Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer, Acta Oncol., 46, 208, 10.1080/02841860600897868 Andreopoulou, 2007, Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer, Clin. Breast Cancer, 7, 690, 10.3816/CBC.2007.n.028 Trudeau, 2009, Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines, J. Clin. Oncol., 27, 5906, 10.1200/JCO.2009.22.7504 Irvin, 2010, Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer, Clin. Breast Cancer, 10, 465, 10.3816/CBC.2010.n.061 Lorusso, 2007, Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome), Ann. Oncol., 18, 1159, 10.1093/annonc/mdl477 Caggiano, 2005, Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy, Cancer, 103, 1916, 10.1002/cncr.20983 Dranitsaris, 2008, Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model, Am. J. Clin. Oncol., 31, 369, 10.1097/COC.0b013e318165c01d Danson, 2004, Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP 1049C) in patients with advanced cancer, Br. J. Cancer, 10.1038/sj.bjc.6601856 Matsumura, 2004, Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin, Br. J. Cancer, 91, 1775, 10.1038/sj.bjc.6602204 Tsukioka, 2002, Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil), Jpn. J. Cancer Res., 93, 1145, 10.1111/j.1349-7006.2002.tb01217.x Kato, 2012, Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer, Invest. New Drugs, 30, 1621, 10.1007/s10637-011-9709-2 Vasey, 1999, Phase I clinical and pharmacokinetic study of PK1 [N – (2- hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic, Clin. Cancer Res., 5, 83 Vicent, 2005, Polymer therapeutics designed for a combination therapy of hormone-dependent cancer, Angew. Chem. Int. Ed. Engl., 44, 4061, 10.1002/anie.200462960 Guo, 2007, Synthesis of alginic acid-poly[2-(diethylamino)ethyl methacrylate] monodispersed nanoparticles by a polymer-monomer pair reaction system, Biomacromolecules, 8, 843, 10.1021/bm060906i Abbasi, 2012, Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment, J. Drug Deliv., 2012, 1, 10.1155/2012/686108 Srinophakun, 2011, Preliminary study of conformation and drug release mechanism of doxorubicin-conjugated glycol chitosan, via cis-aconityl linkage, by molecular modeling, Int. J. Mol. Sci., 12, 1672, 10.3390/ijms12031672 Nagpal, 2010, Chitosan nanoparticles a promising system in novel drug delivery, Chem. Pharm. Bull. (Tokyo), 58, 1423, 10.1248/cpb.58.1423 Sun, 2007, Preparation of nanoparticles composed of chitosan and its derivatives as delivery systems for macromolecules, J. Appl. Polym. Sci., 105, 552, 10.1002/app.26038 Zhang, 2007, Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin, Nanomed. Nanotechnol. Biol. Med., 3, 258, 10.1016/j.nano.2007.08.002 Ying, 2011, Solid lipid nanoparticles modified with chitosan oligosaccharides for the controlled release of doxorubicin, Carbohydr. Polym., 84, 1357, 10.1016/j.carbpol.2011.01.037 Markovsky, 2012, Administration, distribution, metabolism and elimination of polymer therapeutics, J. Control. Release, 161, 446, 10.1016/j.jconrel.2011.12.021 Kabanov, 2002, Pluronic?? block copolymers for overcoming drug resistance in cancer, Adv. Drug Deliv. Rev., 54, 759, 10.1016/S0169-409X(02)00047-9 Batrakova, 2001, Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion, Br. J. Cancer, 85, 1987, 10.1054/bjoc.2001.2165 Asplund, 1994, Hyaluronan receptors are expressed on human malignant mesothelioma cells but not on normal mesothelial cells, Cancer Res., 54, 4516 Dietrich, 1997, High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival, Eur. J. Cancer Part A, 33, 926, 10.1016/S0959-8049(96)00512-6 Cao, 2008, Doxorubicin conjugated to d-??-tocopheryl polyethyleneglycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation, Biomaterials, 29, 3856, 10.1016/j.biomaterials.2008.05.016 Fischer, 2002, Concurrent administration of water-soluble vitamin E can increase the oral bioavailability of cyclosporine a in healthy dogs, Vet. Ther., 3, 465 Rodzinski, 2016, Targeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles, Sci. Rep., 6, 20867, 10.1038/srep20867 Wuang, 2011, Acid-sensitive magnetic nanoparticles as potential drug depots, AIChE J., 57, 1638, 10.1002/aic.12373 Johannsen, 2005, Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique, Int. J. Hyperthermia, 21, 637, 10.1080/02656730500158360 Lübbe, 2001, Clinical applications of magnetic drug targeting, J. Surg. Res., 95, 200, 10.1006/jsre.2000.6030 Torchilin, 2012, Multifunctional nanocarriers, Adv. Drug Deliv. Rev., 64, 302, 10.1016/j.addr.2012.09.031 Munnier, 2008, Novel method of doxorubicin-SPION reversible association for magnetic drug targeting, Int. J. Pharm., 363, 170, 10.1016/j.ijpharm.2008.07.006 Gautier, 2012, A pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for magnetic drug targeting, Int. J. Pharm., 16, 10.1016/j.ijpharm.2011.06.010 Munagala, 2016, Bovine milk-derived exosomes for drug delivery, Cancer Lett., 371, 48, 10.1016/j.canlet.2015.10.020 Tian, 2014, A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy, Biomaterials, 35, 2383, 10.1016/j.biomaterials.2013.11.083 Yang, 2015, Increased anti-tumour activity by exosomes derived from doxorubicin-treated tumour cells via heat stress, Int. J. Hyperthermia, 31, 498, 10.3109/02656736.2015.1036384 Toffoli, 2015, Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin, Nanomedicine, 10, 2963, 10.2217/nnm.15.118 Hadla, 2016, Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models, Nanomedicine, 11, 2431, 10.2217/nnm-2016-0154 Chang, 2003, Multidrug resistance ABC transporters, FEBS Lett., 102, 10.1016/S0014-5793(03)01085-8 Kareva, 2015, Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance, Cancer Lett., 358, 100, 10.1016/j.canlet.2014.12.039 Guo, 2016, A nanoparticulate pre-chemosensitizer for efficacious chemotherapy of multidrug resistant breast cancer, Sci. Rep., 6, 21459, 10.1038/srep21459 Ganoth, 2015, Overcoming multidrug resistance with nanomedicines, Expert Opin. Drug Deliv., 12, 223, 10.1517/17425247.2015.960920 Schell, 2014, Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents, Nanomed. Nanotechnol. Biol. Med., 10, 109, 10.1016/j.nano.2013.07.005 Gabizon, 2002, Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models, J. Drug Target., 10, 539, 10.1080/1061186021000072447 Buyse, 2000, Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis, Lancet, 356, 373, 10.1016/S0140-6736(00)02528-9 Johnson, 2006, Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis, Lancet Oncol., 7, 741, 10.1016/S1470-2045(06)70800-2